Peak THC Responses and Fixed-Time Memory Scores Were Different Statistical Summaries

The oral-THC study summarized several effects by each participant’s peak change from baseline. Its verbal-memory measurement used a fixed assessment time, so the endpoints were not aligned in the same way.

Peak summaries addressed variable timing

The investigators used peak changes for subjective high, dissociative and psychotomimetic measures, and heart rate. Their rationale was that individual differences in the timing of THC effects could obscure response magnitude when everyone was compared at the same clock time.

A peak is not a common moment across participants

A participant-level maximum can occur at different times for different people. Comparing those maxima concerns response magnitude under the sampling schedule; it does not establish that everyone experienced the effect simultaneously. It also differs from the area under an effect-time curve or the duration of a response.

The memory comparison answered another timing question

Verbal learning and recall were assessed once, 80 minutes after administration. Consequently, a difference between the subjective-high finding and the memory null should not automatically be attributed to one mechanism. The endpoints differed both in what they measured and how time entered the analysis. The study’s selected sex difference in high, alongside other null interactions, remains endpoint-specific. An interpretation should preserve that design rather than treating every reported outcome as a simultaneous measurement at a shared THC peak.

Related analysis: the trial’s main results and limitations.

Research cited

Aghaei and colleagues (2024). Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us